-Bradley T Hyman Researcher Activity Profile

Research Author Detailed Information 

Bradley T Hyman Publication Rate By Year

Bradley T Hyman has published 1 paper(s) in 2003, 6 paper(s) in 2006, 26 paper(s) in 2007, 10 paper(s) in 2008, for a total of 43 research publications in total.

Bradley T Bt Hyman Author Information

LAST NAME: hyman

FIRST NAME: Bradley T

INITIALS: bt

AFFILIATION:

Papers

Bradley T Hyman's Publication Record

1. Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. Year Published: 2007
Department of Neurology, Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Bldg. 114-3300, 16th St., Charlestown, MA 02129-4404, USA. touteiro@gmail.com
2. Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high-throughput fluorescent plate reader. Year Published: 2006
Alzheimer's Disease Research Laboratory, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
3. GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. Year Published: 2006
Alzheimer Disease Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
4. Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion. Year Published: 2006
Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA.
5. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. Year Published: 2006
Department of Neurology/Alzheimer's Disease Research Laboratory, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.
6. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Year Published: 2006
Alzheimer's Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, Charlestown, MA 02129, USA. touteir@partners.org
7. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Year Published: 2007
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Harvard New Research Building Room 652, 77 Louis Pasteur Avenue, Boston, MA 02115, USA. Tudor_Fulga@hms.harvard.edu
8. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Year Published: 2007
Alzheimer's Disease Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.
9. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Year Published: 2007
MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Charlestown, MA 02129, USA. bbacskai@partners.org
10. Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Year Published: 2007
MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA. thangram@hotmail.com
11. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Year Published: 2007
Alzheimer's Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA.
12. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Year Published: 2007
Alzheimer Disease Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA.
13. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. Year Published: 2007
Department of Neurology/Alzheimer's Disease Research Laboratory, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.
14. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Year Published: 2007
Stroke and Neurovascular Regulation Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
15. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Year Published: 2007
MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital/ Harvard Medical School, Charlestown, Massachusetts, USA.
16. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Year Published: 2007
Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA, 02129, USA.
17. Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Year Published: 2007
MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA. thangram@hotmail.com
18. Single molecule profiling of tau gene expression in Alzheimer's disease. Year Published: 2007
Department of Neurology, MassGeneral Institute for Neurodegenerative Disease (MIND), Charlestown, Massachusetts, USA. cgc2105@columbia.edu
19. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Year Published: 2007
Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Boston, MA, USA. michael.c.irizarry@gsk.com
20. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Year Published: 2007
Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
21. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Year Published: 2007
Massachusetts General Hospital Gerontology Research Unit and Alzheimer's Disease Research Center, 149 13th St, Suite 2691, Charlestown, MA 02129. bradd@nmr.mgh.harvard.edu.
22. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Year Published: 2007
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. bradd@nmr.mgh.harvard.edu
23. Single molecule profiling of tau gene expression in Alzheimer's disease. Year Published: 2007
Department of Neurology, MassGeneral Institute for Neurodegenerative Disease (MIND), Charlestown, Massachusetts, USA. cgc2105@columbia.edu
24. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Year Published: 2006
Alzheimer's Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, Charlestown, MA 02129, USA. touteir@partners.org
25. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Year Published: 2007
Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden. vilmantas.giedraitis@pubcare.uu.se
26. A limited role for microglia in antibody mediated plaque clearance in APP mice. Year Published: 2007
Massachusetts General Hospital, Department of Neurology/Alzheimer's Disease Research Laboratory, 114 16th Street, #2010, Charlestown, MA 02129, USA.
27. A limited role for microglia in antibody mediated plaque clearance in APP mice. Year Published: 2007
Massachusetts General Hospital, Department of Neurology/Alzheimer's Disease Research Laboratory, 114 16th Street, #2010, Charlestown, MA 02129, USA.
28. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Year Published: 2007
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. bradd@nmr.mgh.harvard.edu
29. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Year Published: 2007
Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Boston, MA, USA. michael.c.irizarry@gsk.com
30. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Year Published: 2007
Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA. martin.ingelsson@pubcare.uu.se
31. Designed helical peptides inhibit an intramembrane protease. Year Published: 2003
Center for Neurologic Diseases, Harvard Medical School, Boston, Massachusetts 02115, USA.
32. TAR-DNA binding protein 43 in Pick disease. Year Published: 2008
Department of Pathology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA. sfreeman1@partners.org
33. In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. Year Published: 2008
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
34. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Year Published: 2008
Alzheimer's Disease Research Laboratory, Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
35. Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Year Published: 2007
MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA. thangram@hotmail.com
36. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Year Published: 2008
Alzheimer's Disease Research Laboratory, Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
37. Plasma {beta} Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study. Year Published: 2008
Uppsala University, Department of Public Health and Geriatrics, Uppsala Science Park, Dag Hammarskölds väg 14B, 751 85 Uppsala, Sweden. lars.lannfelt@pubcare.uu.se.
38. In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. Year Published: 2008
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
39. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Year Published: 2007
Harvard Medical School, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129, USA. martin.ingelsson@pubcare.uu.se
40. Fyn modulation of Dab1 effects on amyloid precursor protein and ApoE receptor 2 processing. Year Published: 2008
Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA.
41. Visualizing interaction of proteins relevant to Alzheimer's disease in intact cells. Year Published: 2008
Department of Neurology, University of Cologne, Germany.
42. Formation of Toxic Oligomeric alpha-Synuclein Species in Living Cells. Year Published: 2008
Alzheimer's Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH Harvard Medical School, Charlestown, Massachusetts, United States of America.
43. Formation of toxic oligomeric alpha-synuclein species in living cells. Year Published: 2008
Alzheimer's Research Unit, MassGeneral Institute for Neurodegenerative Disease, MGH Harvard Medical School, Charlestown, Massachusetts, United States of America. touteiro@fm.ul.pt